Literature DB >> 30181058

A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.

Usha R Lalchandani1, Vaibhav Sahai2, Katherine Hersberger2, Isaac R Francis3, Ashish P Wasnik4.   

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST), including version 1.0 and 1.1, has been universally accepted as the standard response assessment criteria for conventional chemotherapies. Increasing use of immunotherapy led to the need and development of immune-related RECIST. Imaging plays a crucial role in response assessment for solid tumors in guiding patient management as well as in clinical trials. Familiarity to different response criteria will help radiologists to optimally identify, select, and measure tumor lesions per the criteria and assess response to therapy. This article provides a comprehensive review of published RECIST criteria.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30181058     DOI: 10.1067/j.cpradiol.2018.07.016

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  14 in total

1.  Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical status and clinical effect of locally advanced NSCLC patients.

Authors:  Jun-Kai Xu
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

2.  Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients.

Authors:  Zhi Chen; Mei-Xiang Sang; Cui-Zhi Geng; Wei Hao; Hui-Qun Jia
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

3.  A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.

Authors:  L Leon-Mateos; M J Garcia-Velloso; R García-Figueiras; J F Rodriguez-Moreno; J L Vercher-Conejero; M Sánchez; J L Perez Gracia; M Simo-Perdigo; L Gorospe
Journal:  Clin Transl Oncol       Date:  2020-07-04       Impact factor: 3.405

4.  Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanced Pancreatic Cancer.

Authors:  Ci Liu; Haobin Yu; Yue-Hong Hou; Zhen-Lin Gao; Ya-Jing Zhang
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

5.  Clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer, its effect on nutritional status and Changes of peripheral blood T lymphocyte subsets.

Authors:  Wen-Wen Li; Jin Jiao; Zhi-Yu Wang; Ya-Ning Wei; Yuan-Fang Zhang
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

6.  Laparoscopic Radical Resection of Colorectal Cancer in the Treatment of Elderly Colorectal Cancer and Its Effect on Gastrointestinal Function.

Authors:  Biao Liu; Chuanhui Yao; Haiying Li
Journal:  Front Surg       Date:  2022-02-24

7.  Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC.

Authors:  Peng-Zhe Zhou; Lei Gao; Wei Wu; Ying-Xia Hao
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

8.  Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.

Authors:  Jingyu Liu; Jing Li; Hui Wang; Yikai Wang; Qiongzhi He; Xuefeng Xia; Zhe-Yu Hu; Quchang Ouyang
Journal:  J Transl Med       Date:  2019-01-15       Impact factor: 5.531

Review 9.  Thyroid cancer diagnosis in the era of precision imaging.

Authors:  Kimberley-Jane Bonjoc; Hannah Young; Susanne Warner; Thomas Gernon; Ellie Maghami; Ammar Chaudhry
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

10.  Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection.

Authors:  Weigang Xiu; Yin Huang; Yanying Li; Min Yu; Youling Gong
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.